Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0JZGXA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
PSMA-HC41-LD36
|
|||||
| Synonyms |
PSMA-HC41-LD36
Click to Show/Hide
|
|||||
| Organization |
BYONDIS B.V.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-PSMA-HC41
|
Antibody Info | ||||
| Antigen Name |
Glutamate carboxypeptidase 2 (FOLH1)
|
Antigen Info | ||||
| Payload Name |
Seco-DUBA
|
Payload Info | ||||
| Therapeutic Target |
Human deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
PSMA-HC41-LD36 LINKER
|
Linker Info | ||||
| Conjugate Type |
Random coupling of lysine
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 100 nM | Positive PSMA expression (PSMA +++/++) | ||
| Method Description |
In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
|
||||
| In Vitro Model | Prostate carcinoma | LNCaP-C4.2 cells | CVCL_4782 | ||